Pharmacologic blockade or RNA interference of NLRP3 and inhibition of IL-1β with neutralizing antibody reduced pressure overload-induced myocardial hypertrophy (Tang et al., 2020). The gene discussed is NLRP3; the disease is cardiac hypertrophy.